ALB and cardiomyopathy: Mortality was decreased by 54% in patients treated with oral active vitamin D (HR 0.46; 95% CI 0.27–0.81; adjusted for age, gender, underlying renal disease, albumin, calcium, peripheral arterial disease (PAD), diabetes, cardiomyopathy, previous myocardial infarction, cerebrovascular disease, the use of non calcium-based phosphate binders, center, and year of start of PD).